EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Myeloid‐Driven Immune Suppression Subverts Neutralizing Antibodies and T Cell Immunity in Severe COVID‐19

Cong Lai iD, Su Lu, Yilin Yang, Xiaoyu You, Feixiang Xu, Xinran Deng, Lulu Lan, Yuesheng Guo, Zhongshu Kuang, Yue Luo, Li Yuan, Lu Meng und 3 weitere

Journal of Medical Virology · 2025-04 · 97 (4)

DOI: 10.1002/jmv.70335 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 04.04.2025. Verfasst von Cong Lai und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Neutralizing, SARS-CoV-2, Antibodies, Viral. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by the National Key Research and Development Program of China (2021YFC2501800, 2022YFA0806200, 2023YFC0872500, and 2024YFC3044600), the….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The objective of this study was to better understand immune failure mechanisms during severe acute respiratory syndrome coronavirus 2 , SARS‐CoV‐2 infection, which are critical for developing targeted vaccines and effective treatments. We collected 34 cases representing different disease severities and performed high‐quality single‐cell TCR/BCR sequencing to analyze the peripheral immune cell profiles. Additionally, we assessed antibody‐neutralizing activity through in vitro experiments. Our integrated multiomics analysis uncovers a profound immune paradox in severe COVID‐19: hyperinflammation coexists with immunosuppression, driven by distinct yet interconnected dysregulatory mechanisms. Severe patients develop robust humoral immunity, evidenced by clonally expanded plasma cells producing neutralizing antibodies (e.g., IGHG1‐dominated responses) and antigen‐specific T cell activation. However, these protective responses are counteracted by myeloid‐driven immunosuppression, particularly CD14 + HMGB2+ monocytes exhibiting metabolic reprogramming and HLA‐DR downregulation, coupled with progressive T cell exhaustion characterized by IFN‐γ/TNF‐α hyperactivation and impaired antigen presentation. Importantly, prolonged viral persistence in severe cases arises from a failure to coordinate humoral and cellular immunity—antibody‐mediated neutralization cannot compensate for defective cytotoxic T cell function and monocyte‐mediated immune suppression. These findings highlight the necessity for therapeutic strategies that simultaneously enhance antibody effector functions (e.g., Fc optimization), restore exhausted T cells, and reverse myeloid suppression. They also highlight the importance of vaccines designed to elicit balanced B cell memory and durable T cell responses, which are critical to preventing severe disease progression. By addressing the dual challenges of hyperinflammation and immunosuppression, such approaches could restore immune coordination and improve outcomes in severe COVID‐19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antibodies, NeutralizingSARS-CoV-2Antibodies, ViralT-LymphocytesMyeloid CellsImmune ToleranceHumansMaleMiddle AgedFemaleAgedImmunity, HumoralImmunity, CellularAdult

Stichwörter der Autor:innen

BCRCOVID‐19high‐resolution single‐cell transcriptomics peripheral immune responseshumoral immune

Substanzen

Antibodies, NeutralizingAntibodies, Viral

Autor:innen und Institutionen

  • Department of Emergency Medicine, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Institute of Infection and Health, Fudan University, Shanghai, China.
  • Institute of Emergency Rescue and Critical Care, Fudan University, Shanghai, China.
  • Department of Respiratory Medicine, Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai, China.
  • Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.

ORCID-Profile: Cong Lai, Xueling Wu

Förderung

  • This work was supported by the National Key Research and Development Program of China (2021YFC2501800, 2022YFA0806200, 2023YFC0872500, and 2024YFC3044600), the…

Zitieren

APA

Lai, C., Lu, S., Yang, Y., You, X., Xu, F., Deng, X., Lan, L., Guo, Y., Kuang, Z., Luo, Y., Yuan, L., Meng, L., Wu, X., Song, Z., & Jiang, N. (2025). Myeloid‐Driven Immune Suppression Subverts Neutralizing Antibodies and T Cell Immunity in Severe COVID‐19. Journal of Medical Virology, 97(4). https://doi.org/10.1002/jmv.70335

Vancouver

Lai C, Lu S, Yang Y, You X, Xu F, Deng X, et al. Myeloid‐Driven Immune Suppression Subverts Neutralizing Antibodies and T Cell Immunity in Severe COVID‐19. Journal of Medical Virology. 2025;97(4). doi:10.1002/jmv.70335

BibTeX
@article{Lai2025,
  author = {Lai, Cong and Lu, Su and Yang, Yilin and You, Xiaoyu and Xu, Feixiang and Deng, Xinran and Lan, Lulu and Guo, Yuesheng and Kuang, Zhongshu and Luo, Yue and Yuan, Li and Meng, Lu and Wu, Xueling and Song, Zhenju and Jiang, Ning},
  title = {Myeloid‐Driven Immune Suppression Subverts Neutralizing Antibodies and T Cell Immunity in Severe COVID‐19},
  journal = {Journal of Medical Virology},
  year = {2025},
  volume = {97},
  number = {4},
  doi = {10.1002/jmv.70335}
}
Kostenlos starten →